The long-term theme of this grant has been to compare and contrast oligosaccharides (glycans) of normal and malignant cells, and to define the pathological and therapeutic significance of the differences. Sialic acids (Sias) are attached to underlying glycans in various linkages, and can be modified in several ways. Altered expression of specific types and linkages of Sias are prominent features of human and murine tumors. All work in our lab is now focused on the biology and evolution of Sias and Sia-binding proteins in health and disease. Thus, the recent focus of this grant has been on """"""""tumor-specific"""""""" changes in Sia-terminated glycans, and on their interactions with Sia-binding proteins such as Selectins and Siglecs. During the last funding period we completed all of our previously stated aims on Selectins and on alpha2-6-linked Sias in cancer, and also generated novel data about a human-specific diet- and antibody-mediated mechanism for chronic inflammation in tumor progression. The latter involves human metabolic incorporation of the non-human sialic acid N-glycolylneuraminic acid (Neu5Gc) from dietary sources (primarily red meats), in the face of human-specific circulating anti-Neu5Gc antibodies. We also now have preliminary evidence for a second mechanism of human-specific chronic inflammation, involving the reduced expression of inhibitory CD33-related Siglecs (CD33rSiglecs) on leukocytes. Given the known importance of chronic inflammation in carcinoma progression, these two human-specific mechanisms may help explain the unusual propensity of humans (as compared to other primates) to develop carcinomas, and have possible relevance for diagnosis, prognosis and therapy. Thus, the current proposal will focus only on the human-specific changes in Sia biology. The general hypothesis is that the human propensity to develop carcinomas is partly related to Neu5Gc incorporation into tumors in the face of anti-Neu5Gc antibody production, and also to relative leukocyte over-reactivity, arising due to human-specific reduction of CD33rSiglec expression. Our studies will focus on carcinomas of human or syngeneic mouse origin - growing in Cmah-/- mice with a human-like defect in Neu5Gc production and/or in mice with deletions or over-expression of myelomonocytic CD33rSiglecs. We will further explore the significance of Neu5Gc incorporation into primary and metastatic tumors in Cmah-/- mice, in the face of circulating anti-Neu5Gc antibodies, and use mouse models to explore the role of human myelomonocytic cell over-reactivity associated with reduced CD33rSiglec expression in chronic inflammation and progression of primary and metastatic human tumors. Finally, we will ask if the combination of Neu5Gc and anti-Neu5Gc antibodies interactions along with Siglec-deficiency-related myelomonocytic cell hyper-reactivity has even greater facilitating effect on progression of carcinomas. As time allows, we will also do pilot studies of human tumor samples for Neu5Gc expression and infiltrating leukocyte Siglec expression to see if either or both are predictive of prognosis and/or disease progression.

Public Health Relevance

We have found that a non-human molecule in certain foods of animal origin is becoming incorporated from our diet into the human cancers, even while we are making antibodies against it, and that human immune cells are relatively over-reactive to stimuli do to loss of certain inhibitory molecules. These findings have implications for the human propensity to develop carcinomas, and also provide one explanation for the association of red meat consumption with cancer risk. We propose to study all of these issues in detail, using carefully designed mouse models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA038701-28
Application #
8616720
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Sathyamoorthy, Neeraja
Project Start
1985-08-01
Project End
2015-03-31
Budget Start
2014-04-18
Budget End
2015-03-31
Support Year
28
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Läubli, Heinz; Varki, Ajit; Borsig, Lubor (2016) Antimetastatic Properties of Low Molecular Weight Heparin. J Clin Oncol 34:2560-1
Samraj, Annie N; Pearce, Oliver M T; Läubli, Heinz et al. (2015) A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci U S A 112:542-7
Schwarz, Flavio; Fong, Jerry J; Varki, Ajit (2015) Human-specific evolutionary changes in the biology of siglecs. Adv Exp Med Biol 842:1-16
Varki, Nissi M; Varki, Ajit (2015) On the apparent rarity of epithelial cancers in captive chimpanzees. Philos Trans R Soc Lond B Biol Sci 370:
Chang, Yung-Chi; Olson, Joshua; Beasley, Federico C et al. (2014) Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo. PLoS Pathog 10:e1003846
Läubli, Heinz; Alisson-Silva, Frederico; Stanczak, Michal A et al. (2014) Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem 289:33481-91
Pearce, Oliver M T; Läubli, Heinz; Verhagen, Andrea et al. (2014) Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A 111:5998-6003
Pearce, Oliver Mt; Läubli, Heinz; Bui, Jack et al. (2014) Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Oncoimmunology 3:e29312
Samraj, Annie N; Läubli, Heinz; Varki, Nissi et al. (2014) Involvement of a non-human sialic Acid in human cancer. Front Oncol 4:33
Läubli, Heinz; Pearce, Oliver M T; Schwarz, Flavio et al. (2014) Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A 111:14211-6

Showing the most recent 10 out of 84 publications